Acrotech Biopharma
As of the edition of 20 October 2026, Acrotech Biopharma runs 7 drugs, 7 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Vincristine | none listed | 0 |
| Melphalan | none listed | 0 |
| Belinostat | Ended 2026 (patent) | 0 |
| Levoleucovorin | none listed | 0 |
| Pralatrexate | none listed | 3 |
| Ibritumomab tiuxetan | Ended 2014 (computed from the first US licence) | 1 |
| Difamilast | Ends 2036 (patent) | 4 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Acrotech Biopharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 7 trials led
- Immune system: 6 trials led
- Blood and lymph: 5 trials led